MOTS-c vs Retatrutide
Head-to-head comparison of MOTS-c and Retatrutide for research applications. Both peptides are studied for Metabolic Health, but they differ significantly in mechanism, evidence level, and dosing protocols.
Side-by-Side Comparison
| Attribute | Mots C | Retatrutide |
|---|---|---|
| Category | Metabolic / Mitochondrial | Metabolic / Triple Agonist |
| Mechanism | MOTS-c activates AMPK by inhibiting the folate cycle, causing accumulation of AICAR (an AMP analog). | Retatrutide simultaneously activates three receptors: GLP-1 (reduces appetite, slows gastric emptying, improves insulin secretion), GIP (enhances insulin sensitivity, glucose control), and glucagon (increases energy expenditure, fat oxidation, thermogenesis). |
| Evidence Rating | D — Preclinical | B — Phase III / NDA Filed |
| Clinical Status | Research-only / No human clinical trials completed (Phase 1 of analog CB4211 only) | Phase 3 clinical trials (Eli Lilly TRIUMPH program) |
| Safety Profile | No adverse effects reported in preclinical animal studies; Human tolerability is completely unknown for native MOTS-c (no completed human trials) | GI side effects (dose-related, 13-63% across dose groups): nausea, vomiting, diarrhea, constipation; mostly mild to moderate; GI events partially mitigated with lower starting dose (2 mg vs 4 mg initial dose) |
| Route | Subcutaneous | Subcutaneous (clinical trial formulation only) |
| Dose Range | 5–10 mg SC per injection | Phase 2 tested 1, 4, 8, 12 mg weekly SC; optimal dose being determined in Phase 3 |
| Frequency | Once daily or 3–5x weekly | Once weekly |
| Molecular Weight | ~2174.6 g/mol | N/A |
| Half-Life | Several hours; tissue effects may persist longer | ~6 days (allows once-weekly dosing) |
Overview
MOTS-c and Retatrutide are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, dosing protocols, and safety profiles to help researchers understand the key differences and overlaps.
MOTS-c — Mechanism & Evidence
MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) is a 16-amino-acid mitochondrial-derived peptide (MDP) encoded within the mitochondrial 12S rRNA gene (MT-RNR1). Discovered in 2015 by Lee et al. at USC, it acts as a metabolic regulator primarily through AMPK activation. In mouse models, MOTS-c prevents diet-induced obesity and insulin resistance, enhances exercise capacity (old mice ran 2x longer on treadmill tests), and reduces age-related metabolic decline. A modified analog (CB4211) showed good tolerability in a Phase 1 human trial. No clinical trials of native MOTS-c in humans have been completed.
Key claims: Improves insulin sensitivity and glucose metabolism; Exercise mimetic effects; Anti-obesity effects.
Retatrutide 20mg
20mg
Retatrutide 10mg
10mg
Retatrutide — Mechanism & Evidence
Retatrutide is a first-in-class investigational triple hormone receptor agonist (GIP, GLP-1, and glucagon) developed by Eli Lilly. Multiple Phase 3 TRIUMPH trials are ongoing, with TRIUMPH-4 (Dec 2025) reporting average loss up to 71.2 lbs with osteoarthritis pain relief. Expected FDA approval is 2027-2028.
Key claims: Unprecedented weight loss in Phase 2; Phase 3 confirms efficacy with osteoarthritis benefit; Improves glycemic control in type 2 diabetes.
Shared Research Applications
Both peptides are studied for: Metabolic Health.
MOTS-c is also researched for: Anti-Aging.
Retatrutide is also researched for: Weight Management.
Safety Considerations
MOTS-c: No adverse effects reported in preclinical animal studies Human tolerability is completely unknown for native MOTS-c (no completed human trials) Modified analog CB4211 showed good tolerability in Phase 1
Retatrutide: GI side effects (dose-related, 13-63% across dose groups): nausea, vomiting, diarrhea, constipation; mostly mild to moderate GI events partially mitigated with lower starting dose (2 mg vs 4 mg initial dose) Dose-dependent heart rate increases peaking at 24 weeks, declining thereafter
Shop Research Peptides
Retatrutide 20mg
20mg
Retatrutide 10mg
10mg
BPC-157 5mg
5mg
GHK-Cu 50mg
50mg
Tesamorelin 10mg
10mg
BPC-157 10mg
10mg
Tirzepatide 10mg
10mg
KPV 10mg
10mg
Quality Documentation
Review batch documentation before making research purchasing decisions. Volta pairs product education with COA literacy so researchers can evaluate purity, identity, lot details, and testing context.
Product cards on this page link to current catalog entries and available quality documentation.
Related Research News
Retatrutide Buy Online: Research Evidence and Limits
Retatrutide is a tri-agonist peptide under investigation, but no peer-reviewed study confirms over-the-counter availability. This article clarifies what evidence supports and what remains unproven.
MOTS-c Half-Life: What Studies Show and What Remains Unknown
This reference clarifies what primary studies have established about MOTS-c half-life and stability, and identifies the pharmacokinetic questions that remain unanswered in humans.
Retatrutide in Canada: Evidence, Safety, and Access
This article clarifies retatrutide's tri-agonist mechanism, reviews the clinical evidence and its gaps, and outlines legal and safety considerations for Canadian research purchases.
Peptide Tools
Follow Research Updates
Get new research pages, product updates, tool releases, and quality resources from Volta.
Subscribe